Pfizer Inc and BioNTech said on Thursday (April 1) their vaccine is around 91 per cent effective at preventing Covid-19, citing updated trial data that included participants inoculated for up to six months.

The shot also showed early signs of preventing disease in a small subset of study volunteers in South Africa, where a concerning new variant called B.1.351 is circulating.